FDA warns Teva over Copaxone ads

03/19/2012 | Pharmalot.com

Teva's Copaxone display at a recent American Academy of Neurology meeting and a website promoting the multiple sclerosis treatment overstate the drug's safety and efficacy, FDA Office of Prescription Drug Promotion officials said in a letter. Moreover, the website did not include risk information in the text of the Web pages and instead included links to other pages, which the OPDP found misleading.

View Full Article in:

Pharmalot.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX